Transcription of Management of Febrile Neutropenia in Adult Cancer …
{{id}} {{{paragraph}}}
CLINICAL PRACTICE GUIDELINE SUPP-004 Version 3 Management OF Febrile Neutropenia IN Adult Cancer PATIENTS Effective Date: January, 2014 The recommendations contained in this guideline are a consensus of the Alberta Provincial Tumour Teams and are a synthesis of currently accepted approaches to Management , derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care. CLINICAL PRACTICE GUIDELINE SUPP-004 Version 3 SUMMARY OF KEY POINTS 1. Febrile Neutropenia is defined as: Fever higher than C OR higher than C for more than 1 hour, in a patient who has received chemotherapy in the past month, AND Neutrophils less than x 109 cells/L 2.
Comprehensive Cancer Network (NCCN), British Columbia Cancer Agency (BCCA), and Infectious Diseases Society of America (IDSA) were deemed to be most relevant and corresponded best with local context and practice.
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}
Society, Clinical Infectious Diseases, Centers for Disease Control and Prevention, Infectious Diseases Society of America Clinical, Treatment of Drug-Susceptible Tuberculosis, Infectious Diseases Society of America, American Thoracic Society, Infectious Diseases Society, Core Elements, Of America, Management of Adults With Hospital-acquired and, Infectious diseases, Diseases